BBP
Virtus LifeSci Biotech Products ETF
Price Chart
Latest Quote
$89.40
+1.84 (+2.10%)
Current Price
| Previous Close | $87.57 |
| Open | $87.66 |
| Day High | $90.46 |
| Day Low | $87.66 |
| Volume | 17,631 |
Fund Information
| Net Assets | $77.92M |
| Expense Ratio | 0.34% |
| Category | Health |
| Fund Family | Virtus |
| Net Asset Value | $87.59 |
| Premium/Discount | 2.06% |
| Exchange | PCX |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $86.19 |
| SMA50 | $86.23 |
| SMA200 | $79.89 |
| RSI | 56.34 |
| ATR | 1.8269 |
| Rel Volume | 2.63 |
Performance History
| Week | +5.64% |
| Month | +5.99% |
| Quarter | +10.41% |
| 6 Months | +13.79% |
| YTD | +12.20% |
| Year | +50.25% |
| 3 Years | +64.45% |
| 5 Years | +61.72% |
| 10 Years | +235.57% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $89.40 | 17,631 |
| 2026-06-16 | $87.57 | 3,600 |
| 2026-06-15 | $88.06 | 3,000 |
| 2026-06-12 | $87.17 | 1,400 |
| 2026-06-11 | $86.80 | 6,900 |
| 2026-06-10 | $84.63 | 2,800 |
| 2026-06-09 | $85.37 | 3,400 |
| 2026-06-08 | $84.10 | 2,500 |
| 2026-06-05 | $84.71 | 5,600 |
| 2026-06-04 | $86.61 | 4,500 |
| 2026-06-03 | $84.55 | 4,400 |
| 2026-06-02 | $83.56 | 15,900 |
| 2026-06-01 | $84.47 | 7,000 |
| 2026-05-29 | $86.58 | 2,900 |
| 2026-05-28 | $87.24 | 2,900 |
| 2026-05-27 | $87.24 | 3,100 |
| 2026-05-26 | $86.84 | 3,000 |
| 2026-05-22 | $86.11 | 4,100 |
| 2026-05-21 | $86.52 | 15,100 |
| 2026-05-20 | $86.20 | 24,300 |
| 2026-05-19 | $83.92 | 1,300 |
| 2026-05-18 | $84.35 | 4,200 |
About Virtus LifeSci Biotech Products ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.